Tactile Systems Technology Director William W. Burke Sells $135K of Stock
William W. Burke, Director, sold 5,000 shares of Tactile Systems Technology Inc at $27.00 a share, worth $135K in total on Nov 4, 2026. Shares held after the trade: 50,041 (-9.1%).
Tactile Systems Technology Director Laura G. King Sells $120K of Stock
Laura G. King, Director, sold 4,800 shares of Tactile Systems Technology Inc at $25.00 a share, worth $120K in total on Nov 3, 2026. Shares held after the trade: 20,769 (-18.8%).
Tactile Systems Technology reported total revenue of $91.9 million for the quarter ended September 30, 2026, a 7% increase year-over-year, though net income decreased slightly to $7.2 million. The company expanded its portfolio through the acquisition of LymphaTech and an exclusive distribution agreement for the MyoSleeve wearable compression device.
Tactile Systems Technology reported Q3 2026 total revenue of $91.9 million, a 7% increase year-over-year driven by 13% growth in its core lymphedema product line. While gross margin expanded to 77%, net income decreased to $7.2 million from $8.2 million in the prior year due to increased operating expenses supporting growth initiatives.
Term
Q3 2026
“Our results underscore the strength and durability of our core lymphedema business, which delivered its fifth consecutive quarter of double-digit year-over-year revenue growth, while gross margin expanded for the 12th consecutive quarter.”
Sheri Dodd, Chief Executive Officer of Tactile Medical
“We are positioned to capture that opportunity through three connected strategic priorities: expanding access to care, creating value across the patient journey, and broadening treatment options.”
Sheri Dodd, Chief Executive Officer of Tactile Medical